A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC

NCT07086326 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

164

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
Neoadjuvant Therapy
Immunotherapy
AK112
Bispecific Antibody

Interventions

DRUG: Ivonescimab+Chemo
DRUG: Penpulimab+Chemo

Sponsor

Yang Fan, MD